Bacterial and parasitic infections remain major public health challenges, particularly in settings affected by limited diagnostic capacity, antimicrobial resistance, and clinical overlap between infectious diseases caused by different pathogens. Although microbial culture, microscopy, and serological testing remain essential components of laboratory diagnosis, advances in molecular technologies have substantially improved the detection, identification, and genetic characterization of infectious agents. This review examines the scientific principles and clinical applications of conventional and emerging molecular diagnostic approaches, including polymerase chain reaction (PCR), real-time PCR, multiplex nucleic acid amplification, isothermal amplification, CRISPR-based diagnostics, next-generation sequencing (NGS), metagenomic sequencing, and molecular detection of antimicrobial resistance determinants. It also discusses the potential integration of artificial intelligence and bioinformatics into genomic analysis and clinical decision-making. The World Health Organization’s 2025 global antibiotic resistance surveillance report estimated that approximately one in six laboratory-confirmed bacterial infections worldwide in 2023 was resistant to antibiotic treatment. Resistance increased in more than 40% of the pathogen–antibiotic combinations monitored between 2018 and 2023. In tuberculosis diagnosis, the proportion of newly diagnosed patients initially tested using a WHO-recommended rapid diagnostic test increased from 48% in 2023 to 54% in 2024. These findings emphasize the need for accurate, timely, and clinically actionable diagnostic strategies. Molecular diagnostics can improve pathogen identification and support antimicrobial stewardship; however, their clinical value depends on analytical and clinical validation, appropriate specimen selection, quality assurance, and interpretation alongside clinical and epidemiological findings. Future progress will require integration of molecular and conventional methods, investment in laboratory infrastructure, and locally validated diagnostic pathways, particularly in resource-limited settings. Keywords: Molecular diagnostics; bacterial infections; parasitic infections; polymerase chain reaction; next-generation sequencing; antimicrobial resistance; CRISPR; metagenomics; artificial intelligence; medical microbiology. 1. Introduction Accurate diagnosis of bacterial and parasitic infections is fundamental to modern medical practice. It supports appropriate treatment selection, reduces preventable complications, limits unnecessary antimicrobial use, and strengthens infection prevention and control. However, many infectious diseases present with overlapping clinical manifestations. Fever, diarrhoea, respiratory symptoms, and neurological abnormalities may be caused by a wide range of bacterial and parasitic pathogens. Consequently, clinical assessment alone is often insufficient, and laboratory confirmation remains essential for distinguishing among potential causes and guiding management. Traditional diagnostic methods include microbial culture, microscopy, biochemical identification, antigen detection, and serological testing. These methods continue to have substantial clinical value. Culture provides viable isolates for antimicrobial susceptibility testing, microscopy permits direct examination of organisms and parasitic stages, and serological methods can support diagnosis when interpreted within an appropriate clinical context. Nevertheless, some conventional procedures require prolonged incubation, depend on operator expertise, or have limited discriminatory power when pathogens are morphologically similar or difficult to cultivate. Advances in nucleic acid amplification and genomic sequencing have expanded the diagnostic capabilities of clinical microbiology. Molecular methods can detect pathogen-specific DNA or RNA directly from clinical specimens, while multiplex assays can investigate several infectious agents simultaneously. Sequencing approaches provide additional opportunities for species identification, strain characterization, outbreak investigation, and the detection of selected antimicrobial resistance determinants. Metagenomic next-generation sequencing (mNGS), in particular, can investigate a broad range of microorganisms without requiring the pathogen to be specified in advance. However, current evidence supports its use as a complementary diagnostic approach rather than a universal replacement for established methods, because its performance depends on specimen characteristics, microbial burden, contamination control, sequencing depth, and bioinformatic interpretation. This review evaluates established and emerging molecular diagnostic technologies for bacterial and parasitic infections, summarizes their clinical applications and limitations, and discusses opportunities for strengthening diagnostic services, research, and public health surveillance. 2. Clinical Significance of Molecular Diagnostics Molecular diagnostics encompasses methods that detect or characterize pathogen-associated nucleic acids through amplification, sequence analysis, or other genetic approaches. Its clinical importance arises from the ability to identify specific pathogens, distinguish closely related organisms, and detect selected genetic determinants associated with antimicrobial resistance or virulence. The clinical value of a molecular test depends on the pathogen, specimen type, clinical presentation, and intended use. In selected circumstances, molecular assays can provide results within hours, reducing the delay associated with microbial growth. They may also improve identification when conventional microscopy cannot reliably distinguish closely related species. This is particularly relevant to intestinal parasitology, where accurate differentiation between pathogenic and non-pathogenic amoebae can influence clinical interpretation and treatment decisions. A distinction must be made between analytical sensitivity, which describes a test’s ability to detect small amounts of its target, and clinical sensitivity, which reflects its ability to identify infected individuals in a defined clinical population. Similarly, high analytical specificity does not necessarily mean that every positive result represents active disease. A molecular assay may detect residual nucleic acid after an infection has resolved, colonizing organisms unrelated to the patient’s symptoms, or contaminants introduced during specimen collection or processing. Molecular findings should therefore be interpreted alongside clinical, epidemiological, and laboratory evidence. 3. Established and Emerging Molecular Technologies 3.1. Conventional and Real-Time Polymerase Chain Reaction Polymerase chain reaction (PCR) is among the most widely used molecular diagnostic technologies. It amplifies a defined nucleic acid target using sequence-specific primers and a DNA polymerase through repeated cycles of denaturation, primer annealing, and extension. For RNA-based targets, reverse transcription may be performed before amplification, as in reverse-transcription PCR. Real-time PCR, also known as quantitative PCR (qPCR), monitors amplification through fluorescent signals generated during the reaction. Depending on assay design and calibration, it can provide qualitative detection or quantitative estimates of target nucleic acid. Real-time PCR is used in the diagnosis of selected bacterial and parasitic infections, including tuberculosis, sexually transmitted infections, bloodstream infections, and parasitic diseases in which microscopy alone may be insufficient. Reliable results depend on appropriate specimen collection, effective nucleic acid extraction, validated primers and probes, and suitable positive, negative, and internal controls. Internal controls are particularly important for identifying extraction failure or amplification inhibition. A major limitation is that targeted PCR detects only sequences included in its design. Genetic variation in primer- or probe-binding regions may also reduce assay performance, while unanticipated pathogens will remain undetected unless additional testing is undertaken. 3.2. Multiplex Molecular Diagnostics Multiplex PCR allows simultaneous detection of several pathogen targets in a single specimen. This approach is useful when multiple organisms can produce similar clinical syndromes, including infectious diarrhoea, respiratory tract infections, and selected central nervous system infections. By reducing the need for multiple separate assays, multiplex testing may shorten the diagnostic pathway and support more timely clinical decisions. However, increasing the number of targets introduces technical challenges. Primer interactions, differences in amplification efficiency, and target competition can affect performance. Furthermore, detecting several organisms does not establish that all detected organisms are responsible for the patient’s symptoms. This is particularly important in gastrointestinal specimens, where colonization, asymptomatic carriage, and residual nucleic acid may complicate interpretation. Clinical correlation remains essential. 3.3. Isothermal Nucleic Acid Amplification Unlike conventional PCR, isothermal amplification methods operate at a relatively constant temperature and do not require repeated thermal cycling. Loop-mediated isothermal amplification (LAMP) is one of the most widely investigated methods in this category. Other approaches include multiple displacement amplification and several target-specific amplification systems. LAMP has potential applications in the detection of selected bacterial and parasitic pathogens, particularly where access to conventional thermal cyclers is limited. Its relatively simple thermal requirements may facilitate the development of portable diagnostic platforms. Nevertheless, performance varies by assay, target, and specimen type. Primer design can be complex, and contamination by amplified products may cause false-positive results if laboratory procedures are inadequate. Isothermal methods should not automatically be assumed to be more sensitive, faster, or less expensive than PCR in every setting; their suitability must be established through assay-specific validation and operational assessment. 3.4. CRISPR-Based Diagnostics Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins have created new opportunities for nucleic acid detection. Some diagnostic platforms exploit the target-recognition and collateral-cleavage activities of proteins such as Cas12 and Cas13. Target recognition can be coupled to fluorescent or other detection systems, enabling the development of assays with high sequence specificity. SHERLOCK and DETECTR are prominent examples of CRISPR-based diagnostic approaches. These technologies offer design flexibility and may be integrated with lateral-flow devices, microfluidic systems, or portable readers. Such combinations could support rapid pathogen detection outside highly specialized laboratories. However, routine clinical implementation requires independent performance evaluation, standardized workflows, contamination control, validated detection limits, and evidence of clinical utility. Some CRISPR systems also require upstream nucleic acid amplification, which adds complexity and may affect turnaround time. Their future role will depend on whether they can provide reliable and cost-effective results within clearly defined clinical pathways. 3.5. Next-Generation Sequencing and Metagenomic Sequencing Next-generation sequencing (NGS) enables detailed analysis of microbial genetic material and supports species identification, genomic characterization, molecular epidemiology, and the detection of selected resistance determinants. Diagnostic applications include targeted sequencing, which focuses on predefined genes or genomic regions, and untargeted metagenomic sequencing, which investigates nucleic acids within a specimen without restricting analysis to a single anticipated pathogen. Metagenomic next-generation sequencing can detect a broad range of bacteria, parasites, and other microorganisms, including some organisms that are rare, unexpected, or difficult to cultivate. It may be particularly valuable in diagnostically challenging cases, such as unexplained central nervous system infections or infections in immunocompromised patients, when conventional testing has failed to establish a diagnosis. A 2024 review described its applications across multiple clinical settings while emphasizing persistent challenges involving cost, specimen processing, and bioinformatic analysis. Despite its broad detection capability, mNGS does not outperform targeted testing in every situation. Sensitivity may be reduced when microbial nucleic acid is present at low concentrations relative to host-derived nucleic acid. Inadequate extraction procedures, reagent contamination, incomplete reference databases, and inconsistent analytical thresholds can also affect results. Positive findings may reflect contamination or colonization rather than active infection, while negative results do not exclude disease when microbial burden is low or specimen quality is inadequate. Targeted NGS can be more efficient when the likely pathogens or resistance determinants are known in advance. Metagenomic sequencing may be advantageous when the differential diagnosis is broad and standard methods have been inconclusive. In clinical practice, these approaches are best selected according to the diagnostic question and used alongside conventional microbiology whenever culture or phenotypic susceptibility testing remains necessary. 4. Applications in Bacterial Infections 4.1. Detection and Identification of Bacterial Pathogens Molecular methods can detect bacterial pathogens in blood, urine, respiratory specimens, cerebrospinal fluid, and gastrointestinal samples. Targeted assays are useful when the suspected organism is known, whereas multiplex panels can investigate several pathogens associated with the same clinical syndrome. Test selection should reflect the suspected site of infection, specimen type, likely microbial burden, prior antimicrobial exposure, and patient characteristics. In bloodstream infections, rapid molecular assays may accelerate pathogen identification or detection of selected resistance markers. Nevertheless, molecular testing does not invariably provide a viable isolate for subsequent susceptibility testing. Culture and other conventional methods therefore remain important in many clinical situations. A positive molecular result must also be evaluated for clinical relevance. The detection of microbial DNA in a specimen does not always demonstrate that viable organisms are present or that the detected organism is responsible for the clinical syndrome. Combining molecular findings with culture, microscopy, clinical assessment, and other relevant laboratory results provides a more reliable diagnostic framework. 4.2. Molecular Diagnosis of Tuberculosis and Drug Resistance Tuberculosis provides an important example of the clinical impact of rapid molecular diagnostics. Certain validated assays can detect Mycobacterium tuberculosis complex and identify selected genetic markers associated with resistance to specific antituberculosis drugs. This can shorten the time needed to establish a bacteriological diagnosis and may help clinicians select an appropriate initial treatment regimen. According to the World Health Organization’s Global Tuberculosis Report 2025, 8.3 million people were newly diagnosed with and notified as having tuberculosis in 2024. A WHO-recommended rapid diagnostic test was used as the initial test for 4.5 million people, representing approximately 54% of newly diagnosed cases, compared with 48% in 2023. Although this indicates progress in access to rapid testing, a substantial proportion of patients still do not receive a recommended rapid test as their initial diagnostic procedure. Molecular resistance testing is particularly valuable when resistance information can alter treatment decisions. However, a molecular assay may detect only a defined subset of resistance-associated mutations. Other mechanisms may remain undetected, and genotype–phenotype relationships can vary by drug and organism. Phenotypic susceptibility testing and additional molecular investigations remain necessary when recommended by clinical guidelines or when results are inconclusive. 4.3. Molecular Detection of Antimicrobial Resistance Antimicrobial resistance (AMR) is a major driver of the development and implementation of rapid molecular diagnostics. Molecular tests can identify selected genes or mutations associated with resistance, including certain extended-spectrum beta-lactamases, carbapenemases, and mutations associated with antituberculosis drug resistance. Such information can support antimicrobial selection, infection prevention and control, and epidemiological surveillance. The WHO Global Antibiotic Resistance Surveillance Report 2025 estimated that approximately one in six laboratory-confirmed bacterial infections worldwide in 2023 was resistant to antibiotic treatment. The report analysed more than 23 million bacteriologically confirmed cases reported by 104 countries in 2023. It also documented an increase in resistance across more than 40% of the pathogen–antibiotic combinations monitored between 2018 and 2023. These findings strengthen the case for diagnostic approaches that can rapidly identify pathogens and selected resistance markers. Nevertheless, detecting a resistance gene does not always establish the degree of clinical resistance, and failure to detect a particular gene does not exclude other resistance mechanisms. Gene expression, additional mutations, and organism-specific biological factors may influence the final phenotype. Molecular results should therefore be integrated with phenotypic antimicrobial susceptibility testing whenever the latter is indicated and available. 5. Applications in Parasitic Infections 5.1. Intestinal Protozoa and Other Enteric Parasites The diagnosis of intestinal parasitic infections is complicated by intermittent shedding, variable parasite burden, differences in specimen quality, and morphological similarities among species. Microscopy remains important, but it may not reliably distinguish certain closely related intestinal amoebae. Misidentification can result in inaccurate clinical interpretation and unnecessary treatment. PCR and multiplex molecular assays can detect species-specific genetic targets in selected intestinal protozoa, including Entamoeba histolytica, Giardia duodenalis, and Cryptosporidium species. These methods may improve species discrimination and diagnostic sensitivity in situations where microscopy is limited by low organism numbers or morphological overlap. Their interpretation must nevertheless account for clinical presentation, epidemiological exposure, specimen type, and the possibility that the detected organism is not responsible for the current symptoms. Sequencing methods can also support the study of genetic diversity, strain distribution, and transmission patterns in parasitic infections. However, their routine implementation depends on infrastructure, technical expertise, cost, and the availability of validated reference databases. Molecular methods should complement, rather than automatically replace, microscopy, antigen detection, histopathology, and other established diagnostic procedures. 5.2. Malaria and Vector-Borne Parasitic Diseases Microscopy and rapid diagnostic tests remain central to routine malaria diagnosis under WHO guidance. Molecular methods, including PCR and selected isothermal amplification technologies, can provide high analytical sensitivity for detecting low-density infections and can support species identification in epidemiological and research settings. However, molecular testing is not necessarily the preferred first-line approach for every suspected malaria case. The appropriate method depends on the clinical objective, urgency, local infrastructure, and applicable guidelines. WHO currently advises that nucleic acid amplification tests for malaria be considered primarily for research purposes until further evidence clarifies the public health impact of detecting and treating low-density infections. Molecular methods also have applications in the study of parasite diversity, transmission, and selected drug-resistance markers. In leishmaniasis, validated molecular assays can support parasite detection and species identification in appropriate specimens. Performance depends on the clinical form of disease, the anatomical site sampled, the amount of parasite DNA present, and the assay used. 5.3. Parasite-Specific Diagnostic Challenges Molecular diagnosis of parasitic infections requires careful consideration of parasite biology, life cycle, anatomical distribution, and specimen selection. A negative result may occur when parasite shedding is intermittent, when the wrong specimen is collected, or when the organism is present below the detection limit. Nucleic acid degradation, amplification inhibitors, and inadequate extraction may also reduce sensitivity. Furthermore, the detection of parasite nucleic acid does not necessarily establish parasite viability or causation of disease. Genetic material may persist after the clinical infection has declined, and a detected organism may be non-pathogenic or unrelated to the patient’s symptoms. Accurate diagnosis therefore requires integration of molecular results with clinical findings, epidemiological information, and complementary laboratory tests. 6. Integration of Artificial Intelligence and Bioinformatics The growing availability of genomic data has increased the need for reliable bioinformatic systems capable of processing large sequence datasets, comparing them with reference databases, identifying organisms, and detecting genetic markers associated with resistance. Artificial intelligence and machine learning may support selected analytical tasks by recognizing patterns, prioritizing findings, and identifying relationships that warrant further investigation. The reliability of these systems depends on the quality and representativeness of the training data, the completeness of reference databases, and independent validation of model performance. Incomplete databases or inaccurate annotations can lead to misclassification. Similarly, a statistical association between a genetic marker and resistance does not necessarily establish causality or guarantee a clinically meaningful resistance phenotype. AI should therefore be regarded as a decision-support tool rather than a replacement for laboratory expertise or clinical judgement. Safe implementation requires transparent analytical workflows, appropriate data protection, independent validation, and human review of unexpected or clinically consequential findings. 7. Comparative Overview of Molecular Diagnostic Technologies Technology Primary application Main advantages Important limitations Conventional PCR and real-time PCR Detection of predefined genetic targets High analytical accuracy when validated; relatively rapid results Limited to targets included in assay design Multiplex PCR Simultaneous detection of several pathogens Reduced need for separate tests; faster syndromic investigation Potential target interference; complex interpretation of multiple detections LAMP and other isothermal methods Nucleic acid detection without thermal cycling Potential for simpler and portable platforms Assay-dependent performance; contamination and validation challenges CRISPR-Cas diagnostics Sequence-specific pathogen detection Flexible target design; potential integration with simple readout systems Clinical validation and standardization remain necessary Targeted NGS Detailed analysis of selected genes or genomic regions Rich genetic information; potential resistance-marker detection Cost, workflow complexity, and bioinformatic requirements Metagenomic NGS Broad pathogen investigation without a predefined target Potential value in complex or unexplained infections High cost; contamination, sensitivity, and interpretation challenges Molecular resistance testing Detection of selected resistance genes or mutations Supports treatment decisions and surveillance Does not invariably replace phenotypic susceptibility testing No single technology is optimal for every diagnostic scenario. The choice should reflect the clinical question, specimen characteristics, suspected pathogens, turnaround time, local resources, and the likelihood that the result will change treatment or infection-control decisions. 8. Barriers to Wider Clinical Implementation Despite rapid technological progress, molecular diagnostics faces several barriers to routine implementation. These include the cost of instruments and reagents, the need for trained personnel, maintenance requirements, supply-chain stability, and the standardization of specimen collection, transport, and processing. Advanced assays also require robust internal and external quality assurance, documented validation, and clear procedures for handling inconclusive or discordant results. Interpretation becomes particularly challenging when multiple organisms are detected or when the detected genetic material does not match the clinical presentation. Metagenomic sequencing may identify environmental contaminants, reagent-derived sequences, or colonizing organisms. A positive result should therefore not be interpreted in isolation, and a negative result should not automatically exclude infection when specimen quality or assay sensitivity is inadequate. Unequal access to diagnostic infrastructure may also widen differences in healthcare quality. A rational implementation strategy should prioritize technologies according to local disease burden, clinical need, cost-effectiveness, and feasibility. Introducing expensive platforms without demonstrating their clinical or public health value may not be sustainable, particularly in resource-constrained healthcare systems. 9. Future Perspectives and Relevance to Iraq Advanced molecular diagnostics offers important opportunities for strengthening clinical microbiology in Iraq, particularly in university hospitals, referral centres, and laboratories involved in infectious disease surveillance. However, adoption should be based on local needs assessment, identification of priority pathogens, economic evaluation, workforce capacity, and infrastructure readiness. Practical priorities include strengthening reference laboratories, standardizing specimen collection and transport, implementing quality-assurance programmes, training personnel in molecular interpretation, and linking laboratory findings with clinical and epidemiological data. Collaboration among universities, hospitals, and research institutions could support local validation studies comparing molecular assays with appropriate reference methods and evaluating their effects on diagnostic accuracy, turnaround time, antimicrobial prescribing, and patient outcomes. For antimicrobial resistance, molecular assays may support early detection of clinically important resistance determinants, while culture and phenotypic susceptibility testing should remain available when required. In parasitology, locally relevant research could investigate molecular differentiation of closely related species, geographic distribution of pathogenic parasites, and the relationship between molecular findings and clinical outcomes. Importantly, global estimates should not be interpreted as direct estimates of the situation in Iraq. International statistics provide essential context but cannot replace representative national data. Iraqi studies should clearly report study location, study period, sample size, inclusion and exclusion criteria, diagnostic reference methods, and relevant measures of uncertainty. Prevalence estimates should be accompanied by appropriate confidence intervals, while diagnostic performance studies should report sensitivity, specificity, predictive values where appropriate, and the methods used to establish reference status. Findings from a single hospital or region should not be generalized to the entire country without supporting evidence. 10. Conclusion Advanced molecular diagnostics has substantially expanded the capacity to detect and characterize bacterial and parasitic infections. PCR and multiplex assays offer practical solutions for defined clinical questions, while isothermal amplification and CRISPR-based approaches may facilitate the development of simpler diagnostic platforms. NGS and metagenomic sequencing provide broader opportunities for investigating complex infections, characterizing microbial diversity, and detecting selected genetic markers associated with antimicrobial resistance. Nevertheless, technological novelty alone does not guarantee clinical benefit. Diagnostic performance depends on specimen quality, assay validation, the relevance of the selected target, and interpretation within the clinical context. The most effective diagnostic strategy is therefore an integrated approach that combines molecular methods with culture, microscopy, phenotypic susceptibility testing, and other relevant investigations. Investment in molecular diagnostic infrastructure, workforce development, quality assurance, and locally designed research could improve pathogen identification, support antimicrobial stewardship, and strengthen public health surveillance. Well-designed Iraqi studies will be essential for determining which technologies provide the greatest clinical and economic value within the country’s healthcare system. Dr. Asseel Hashim Radhi